EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase

Yuliya Tishova, Svetlana Kalinchenko, George Mskhalaya, Geoffrey Hackett, Mark Livingston, Carola König, Richard Strange, Michael Zitzmann, Amar Mann iD, Amro Maarouf, Sudarshan Ramachandran

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15520 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Yuliya Tishova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Medical Clinic K-medicine, Moscow, Russia. Hauptthemen laut MEDLINE: Metabolic Syndrome, Testosterone, Insulin Resistance, Hypogonadism. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: North Staffordshire Medical Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To describe changes in homeostasis model assessment of insulin resistance index (HOMA‐IR) following testosterone therapy in men with hypogonadism and metabolic syndrome (MetS). Materials and Methods A randomized, placebo‐controlled, double‐blind randomized controlled trial (RCT) comprising 184 men with MetS and hypogonadism (testosterone undecanoate [TU]: 113 men, placebo: 71 men) was conducted. This was followed by an open‐label phase in which all men were given TU. We focused on men who were not receiving antiglycaemic agents (TU: 81 men; placebo: 54 men) as these could affect HOMA‐IR. Inter‐group comparison of HOMA‐IR was restricted to the RCT (30 weeks), whilst intra‐group comparison was carried out on men provided TU during the RCT and open‐label phases (study cohort) and men given placebo during the RCT and then switched to TU during the open‐label phase (confirmatory cohort). Regression analysis was performed to identify factors associated with change in HOMA‐IR (∆HOMA‐IR).

Results

The median HOMA‐IR was significantly reduced at almost every time point (after 18 weeks) compared to baseline in men receiving TU in both the study and confirmatory cohorts. There was a significant decrease in median values of fasting glucose (30 weeks: −2.1%; 138 weeks: −4.9%) and insulin (30 weeks: −10.5%; 138 weeks: −35.5%) after TU treatment. Placebo was not associated with significant ∆HOMA‐IR. The only consistent predictor of HOMA‐IR decrease following TU treatment was baseline HOMA‐IR ( r 2 ≥ 0.64).

Conclusions

Baseline HOMA‐IR predicted ΔHOMA‐IR, with a greater percentage change in insulin than in fasting glucose. In men with MetS/type 2 diabetes (T2DM) not on antiglycaemic therapy, improvements in HOMA‐IR may be greater than suggested by change in fasting glucose. Our results suggest that hypogonadism screening be included in the management of men with MetS/T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeTestosteroneInsulin ResistanceHypogonadismHumansMaleDouble-Blind MethodMiddle AgedAdultHormone Replacement TherapyBlood GlucoseAged

Stichwörter der Autor:innen

adult‐onset hypogonadisminsulin resistancemetabolic syndrometestosterone therapywaist circumference

Substanzen

Testosteronetestosterone undecanoateBlood Glucose

Autor:innen und Institutionen

  • Department of Endocrinology, Medical Clinic K-medicine, Moscow, Russia.
  • Department of Endocrinology, People's Friendship University of Russia, Moscow, Russia.
  • Department of Preventive Medicine, European Medical Center, Moscow, Russia.
  • School of Health and Life Sciences, Aston University, Birmingham, UK.
  • Department of Clinical Biochemistry, Black Country Pathology Services, Walsall Manor Hospital, UK.
  • School of Medicine and Clinical Practice, Faculty of Science and Engineering, The University of Wolverhampton, Wolverhampton, UK.

ORCID-Profile: Amar Mann

Förderung

  • North Staffordshire Medical Institute

Zitieren

APA

Tishova, Y., Kalinchenko, S., Mskhalaya, G., Hackett, G., Livingston, M., König, C., Strange, R., Zitzmann, M., Mann, A., Maarouf, A., & Ramachandran, S. (2024). Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15520

Vancouver

Tishova Y, Kalinchenko S, Mskhalaya G, Hackett G, Livingston M, König C, et al. Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15520

BibTeX
@article{Tishova2024,
  author = {Tishova, Yuliya and Kalinchenko, Svetlana and Mskhalaya, George and Hackett, Geoffrey and Livingston, Mark and König, Carola and Strange, Richard and Zitzmann, Michael and Mann, Amar and Maarouf, Amro and Ramachandran, Sudarshan},
  title = {Testosterone therapy reduces insulin resistance in men with adult‐onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open‐label phase},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15520}
}
Kostenlos starten →